Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland.
Acute coronary syndromes
COVID-19
Health care system
Non-ST-segment acute coronary syndrome (NSTE-ACS)
Non-ST-segment myocardial infarction
Percutaneous coronary intervention
Regulatory Authorities
ST-segment elevation myocardial infarction
Switzerland
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
22
09
2020
revised:
17
11
2020
accepted:
23
11
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
To investigate the effect of the corona virus disease 2019 (COVID-19) pandemic on the acute treatment of patients with ST-segment elevation (STEMI) and Non-ST-segment elevation acute coronary syndrome (NSTE-ACS). We retrospectively identified patients presenting to the emergency department (ED) with suspected ACS. We evaluated the number of percutaneous coronary interventions (PCIs) for STEMI, NSTE-ACS, and elective PCI cases. In STEMI patients, we assessed the time from chest pain onset (cpo) to ED presentation, post-infarction left ventricular ejection fraction (LVEF), and time from ED presentation to PCI. We directly compared cases from two time intervals: January/February 2020 versus March/April 2020 (defined as 2 months before and after the COVID-19 outbreak). In a secondary analysis, we directly compared cases from March/April 2020 with patients from the same time interval in 2019. From January to April 2020, 765 patients presented with acute chest pain to the ED. A dramatic reduction of ED presentations after compared to before the COVID-19 outbreak (31% relative reduction) was observed. Overall, 398 PCIs were performed, 220/398 PCIs (55.3%) before versus 178/398 PCIs (44.7%) after the outbreak. While numbers for NSTE-ACS and elective interventions declined by 21% and 31%, respectively, the number of STEMI cases remained stable. Time from cpo to ED presentation, post-infarction LVEF, and median door-to-balloon time remained unchanged. In contrast to previous reports, our findings do not confirm the dramatic drop in STEMI cases and interventions in northwestern Switzerland as observed in other regions and hospitals around the world.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the effect of the corona virus disease 2019 (COVID-19) pandemic on the acute treatment of patients with ST-segment elevation (STEMI) and Non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
METHODS
METHODS
We retrospectively identified patients presenting to the emergency department (ED) with suspected ACS. We evaluated the number of percutaneous coronary interventions (PCIs) for STEMI, NSTE-ACS, and elective PCI cases. In STEMI patients, we assessed the time from chest pain onset (cpo) to ED presentation, post-infarction left ventricular ejection fraction (LVEF), and time from ED presentation to PCI. We directly compared cases from two time intervals: January/February 2020 versus March/April 2020 (defined as 2 months before and after the COVID-19 outbreak). In a secondary analysis, we directly compared cases from March/April 2020 with patients from the same time interval in 2019.
RESULTS
RESULTS
From January to April 2020, 765 patients presented with acute chest pain to the ED. A dramatic reduction of ED presentations after compared to before the COVID-19 outbreak (31% relative reduction) was observed. Overall, 398 PCIs were performed, 220/398 PCIs (55.3%) before versus 178/398 PCIs (44.7%) after the outbreak. While numbers for NSTE-ACS and elective interventions declined by 21% and 31%, respectively, the number of STEMI cases remained stable. Time from cpo to ED presentation, post-infarction LVEF, and median door-to-balloon time remained unchanged.
CONCLUSIONS
CONCLUSIONS
In contrast to previous reports, our findings do not confirm the dramatic drop in STEMI cases and interventions in northwestern Switzerland as observed in other regions and hospitals around the world.
Identifiants
pubmed: 33335974
doi: 10.1016/j.ijcha.2020.100686
pii: S2352-9067(20)30384-5
pmc: PMC7734221
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100686Informations de copyright
© 2020 The Author(s).
Références
Eur Heart J. 2020 May 14;41(19):1852-1853
pubmed: 32297932
Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):210-216
pubmed: 32467968
Eur Heart J Qual Care Clin Outcomes. 2020 Jul 1;6(3):223-224
pubmed: 32348457
Am Heart J. 2020 Aug;226:45-48
pubmed: 32497914
Catheter Cardiovasc Interv. 2020 Jun 1;:
pubmed: 32478961
Eur Heart J. 2020 Oct 7;41(38):3743-3749
pubmed: 33029615
Circulation. 2020 Jun 16;141(24):2035-2037
pubmed: 32352318
Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e006938
pubmed: 32524835
Postgrad Med J. 2020 Jul;96(1137):436-437
pubmed: 32522847
Clin Res Cardiol. 2020 Dec;109(12):1511-1521
pubmed: 32676681
Am J Emerg Med. 2020 Jun 6;:
pubmed: 32540217
J Am Coll Cardiol. 2020 Jun 9;75(22):2871-2872
pubmed: 32283124
EuroIntervention. 2020 Aug 28;16(5):371-379
pubmed: 32065586
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Eur J Intern Med. 2017 Nov;45:8-12
pubmed: 29074217
G Ital Cardiol (Rome). 2020 Jul;21(7):502-508
pubmed: 32555565
Eur Heart J. 2020 Jun 7;41(22):2083-2088
pubmed: 32412631
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131
Blood. 2020 Jul 23;136(4):489-500
pubmed: 32492712